Work

Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD

Year: 2020

Type: article

Study design: Clinical Trial

Source: Multiple Sclerosis and Related Disorders

DOI: 10.1016/j.msard.2020.101957

Authors: Gary Cutter, Antonella Veneziano, Augusto Grinspan, Mahir Al-Banna, Alexey Boyko, Maria Zakharova, Eva Maida, Marija Bosnjak Pasic, Sanjay K. Gandhi, Robin Everts, Cinzia Cordioli, Silvia Rossi

Institutions: University of Alabama at Birmingham, Birmingham Repertory Theatre, Teva Pharmaceuticals (United States), Pirogov Russian National Research Medical University, Research Center of Neurology, University Hospital Centre Zagreb, Ministry of Health, University of Osijek, Fondazione IRCCS Istituto Neurologico Carlo Besta

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, Teva Pharmaceutical Industries

OpenAlex ID: W3002622012

FWCI: 0.84

Cites: 23

Cited by: 10

Related to: 10